Tirzepatide
SURMOUNT-2
Eli Lilly · Phase 3 · Completed · Enrollment 938
| Arm | Nausea | Vomiting | Diarrhea | Discontinuation | Deaths |
|---|---|---|---|---|---|
| 10 milligrams (mg) Tirzepatide | n/r | n/r | n/r | n/r | n/r |
| 15 mg Tirzepatide | 68 participants | 40 participants | 66 participants | n/r | 0 |
| Placebo | 20 participants | 10 participants | 28 participants | n/r | 0 |
| 10 mg Tirzepatide | 63 participants | 34 participants | 62 participants | n/r | 2 |
A count stays a count. This page does not turn a count into a percent.